Ewing's Sarcoma and Primitive Neuroectodermal Family of Tumors
Section snippets
Epidemiology and clinical features
ES is the second most common primary malignancy of bone. It is a disease primarily of children and young adults and is rarely seen in older adults. In the United States, approximately 300 cases of ES are diagnosed in children and adolescents under the age of 20 each year. There is a slight male predominance, with an average annual rate of 3.3 per million in men and 2.6 per million in women [8]. The peak incidence in men is between the ages of 10 and 14 years, whereas in women it is between the
Genetic and molecular characterization
Over 85% of analyzed cases of ES are characterized by a t(11;22)(q24;q12) translocation [2], [34], [35], [36], [37]. This translocation is also seen in pPNET [38], reflecting the common histogenesis shared with ES. The result of this translocation is the fusion of the ews gene, which encodes for an RNA-binding protein of unknown function and is located at 22q12, with the human homolog of the murine FLI1 gene, a member of the ETS family of transcription factors that is located at 11q24 [39]. The
Treatment of localized Ewing's sarcoma family of tumors
Before the development of effective chemotherapy, local control measures alone were used for the treatment of localized ESB with 5-year survival rates of 10% to 20% [49], [50], [51], [52], [53], [54]. Subclinical metastatic disease is now assumed to be present in nearly all patients because of the significant relapse rate seen in patients who have undergone local treatment without systemic chemotherapy. Micrometastatic disease in the bone marrow has been detected by reverse
Treatment of metastatic disease
Approximately 20% to 25% of patients who have EFT have overt metastases at the time of diagnosis [24], [27], [112], [113]. Patients who present with metastatic disease continue to have a poor prognosis with a 5-year relapse free survival (RFS) rate of 30% [27]. There is a trend toward better survival for those with lung involvement alone as compared with those with bone metastases or a combination of lung and bone disease [114]. Many patients who have metastatic disease at diagnosis respond
Treatment of progressive and relapsed disease
The outcome is poor once patients have relapsed, particularly for those relapsing within 2 years of diagnosis [27]. A recent study from SJCRH revealed a 17% 5-year postrecurrence survival. Those who had relapse more than 2 years after diagnosis, those who had local recurrence alone that could be treated with radical surgery and intensive chemotherapy, and those who had isolated pulmonary metastases treated with WLI fared better [119].
Studies performed in the early 1980s found significant
Stem cell transplantation in the treatment of Ewing's sarcoma family of tumors
In an effort to improve outcome, particularly for high-risk patients, the role high-dose myeloablative therapy followed by stem cell rescue has been investigated. It was hoped that increased dose-intensity would increase the fraction of tumor cells destroyed, thus leading to an increased probability of long-term EFS. Several small series and case reports suggested improved clinical outcomes with stem cell transplantation (SCT) [113], [127], [128], [129], [130], [131], [132], [133], [134], [135]
Risk for secondary malignancy after curative therapy
Treatment-related acute myeloblastic leukemia and myelodysplastic syndrome (t-AML/MDS) have been reported in 1% to 2% of survivors of EFT [158], [159], [160]. These secondary malignancies occur most commonly between 2 and 5 years following diagnosis [159], [160]. The advent of protocols that include intensification of alkylators and topoisomerase-II inhibitors has resulted in a significant increase in the incidence of t-AML/MDS [144]. The cumulative incidence of t-AML/MDS was 8% in survivors of
Current clinical trials and prospects for future studies
The prognosis for patients who have EFT has improved dramatically with the advent of combined modality therapy [62], [63], [64], [65]. Despite these advancements in therapy, a significant proportion of patients develop recurrent disease and eventually succumb to their disease. Therefore, continued investigation of novel treatment strategies is important to further improve the outcome of these patients.
Immunohistochemical studies performed on EFT have shown that approximately 70% of samples
References (175)
- et al.
Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior
Hum Pathol
(1999) - et al.
Rarity of Ewing's sarcoma in China
Lancet
(1980) - et al.
A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346
Int J Radiat Oncol Biol Phys
(1998) - et al.
Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG)
Eur J Cancer
(1999) - et al.
Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases and remarkable consistency of t(11;22)(q24;q12)
Cancer Genet Cytogenet
(1988) - et al.
Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome
Hum Pathol
(2002) - et al.
Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients
Int J Radiat Oncol Biol Phys
(1990) - et al.
Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy
Int J Radiat Biol Phys
(1991) - et al.
Long-term results from the first UKCCSG Ewing's tumor study (ET-1)
Eur J Cancer
(1997) - et al.
Neoadjuvant chemotherapy for Ewing's tumor of bone: recent experience at the Rizzoli Orthopaedic Institute
Eur J Cancer
(2002)
Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial
Int J Radiat Oncol Biol Phys
Effects of 4-hydroperoxyifosfamide in combination with other anticancer agents on human cancer cell lines
J Orthop Sci
Diffuse endothelioma of bone
Proc NY Pathol Soc
The Ewing family of tumors: a subgroup of small-round-cell tumors defined by specific chimeric transcripts
N Engl J Med
Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma
Cancer
Prognostic value of clinicopathologic characteristics including neuroectodermal differentiation in osseous Ewing's sarcoma family of tumors in children
Tumori
Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the Istituto Rizzoli
J Clin Oncol
Neural differentiation and prognosis in peripheral primitive neuroectodermal tumor
J Clin Oncol
SEER Cancer Statistics Review, 1975–2001
Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases from the Children's Cancer Group
Cancer
Incidence of cancer in children in the United States
Cancer
Primary bone cancer incidence in black and white residents of New York state
Cancer
Epidemiology of bone cancer in children
J Natl Cancer Inst
Comparative frequency of bone sarcomas among different racial groups
Chin Med J (Engl)
Interethnic polymorphism of EWS intron 6: genome plasticity mediated by Alu retroposition and recombination
Hum Genet
Stature and malignant tumors of bone in childhood and adolescence
Cancer
Stature and Ewing's sarcoma in childhood
Am J Pediatr Hematol Oncol
A case-control study of the etiology of Ewing's sarcoma
Cancer Epidemiol Biomarkers Prev
Ewing's bone sarcoma, paternal occupational exposure, and other factors
Am J Epidemiol
Cancer Incidence in the families of children with Ewing's sarcoma
J Natl Cancer Inst
Risk of cancer in families of patients with Ewing's sarcoma family of tumors
Ann Meet Am Assoc Cancer Res
A cancer family syndrome in twenty-four kindreds
Cancer Res
Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and The Medical Research Council Ewing's Tumor Study
J Clin Oncol
Extraskeletal Ewing's sarcoma: a case report and review of the literature
Spine
Neurogenic tumors of soft tissue
Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group
J Clin Oncol
Prognostic significance of serum LDH in Ewing's sarcoma of bone
Oncol Rep
Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma
Acta Oncol
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86
J Clin Oncol
Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience
Cancer
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone
N Engl J Med
Chromosomal translocations in Ewing's sarcoma
N Engl J Med
Chromosomal translocations in Ewing's sarcoma
N Engl J Med
Gene rearrangements in Ewing's sarcoma
Cancer Invest
Cytogenetic and molecular cytogenetic techniques in orthopaedic surgery
J Bone Joint Surg Am
Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoint
Genes Chromosomes Cancer
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma
J Clin Oncol
Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma
Am J Pathol
A new member of the ETS family fused to EWS in Ewing tumors
Oncogene
Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis
Jpn J Cancer Res
Cited by (125)
Primary retroperitoneal Ewing's sarcoma in a young woman
2024, Asian Journal of SurgeryA rare case of Ewing's sarcoma of the maxillary sinus
2023, Radiology Case ReportsNeoadjuvant chemotherapy for Ewing's sarcoma family tumors of the uterine cervix: A case report
2021, Gynecologic Oncology ReportsExtraskeletal Ewing sarcoma of the buccal space
2021, Clinical ImagingCitation Excerpt :This anatomical location confers an especially poor prognosis for pediatric patients.3 The most common treatment for EES of the head and neck is multimodal, involving surgical resection or radiotherapy with neoadjuvant chemotherapy.5 Due to its rarity, much remains unknown about the optimal management of EES in the head and neck, and radiographic examination plays a markedly important role in its diagnosis, treatment, and surveillance.
Primitive Neuroectodermal Tumor as the Second Malignant Neoplasm in a Long-Term Survivor Child of Acute Lymphoblastic Leukemia: A Case Report
2020, Chinese Medical Sciences JournalPediatric Ewing sarcoma of the head and neck: A retrospective survival analysis
2019, International Journal of Pediatric OtorhinolaryngologyCitation Excerpt :The majority of cases of Ewing sarcoma occur in patients under the age of twenty [2]. The tumor has a slight male predominance and is nine times more likely to occur in white children than African-American children [1]. While the incidence of Ewing sarcoma between 1973 and 2004 was 2.93 cases per million people, only 3.8% of cases are in the head and neck [3,4].